Sulfur Containing Patents (Class 424/117)
  • Patent number: 8609083
    Abstract: This invention relates to using bacterial metabolites to suppress phytopathogens, more particularly this invention relates to bacterial metabolites applied to Carya illinoensis and Prunus persica as a fungicide to suppress and inhibit Glomerella cingulata, Phomopsis sp., Phytophthora cactorum, Fusicladosporium effusum, and Monilinia fructicola.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: December 17, 2013
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: David I. Shapiro-Ilan, Charles C. Reilly
  • Patent number: 7851439
    Abstract: Organic compounds that are useful for the treatment, prevention and/or amelioration of diseases are described.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: December 14, 2010
    Assignee: Novartis AG
    Inventors: Simon Bushell, Matthew LaMarche, Michael J. Patane, Lewis Whitehead
  • Patent number: 6844182
    Abstract: This invention is directed to Bacillus mutants which produce a factor which potentiates the pesticidal activity of a Bacillus related pesticide, a chemical pesticide and/or a virus with pesticidal properties.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: January 18, 2005
    Assignee: Valent BioSciences Corporation
    Inventors: Helle Outtrup, William D. Lidster, Susan C. MacIntosh, Robert L. Starnes, Denise Carol Manker
  • Publication number: 20030202957
    Abstract: The field of colonic diagnostic and surgical procedures is hampered by the lack of optimal means available to cleanse the colon. A compromise between convenient, distasteful, solid or low volume, hyperosmotic solutions which cause considerable fluid and electrolyte imbalances in patients and large volume, difficult to consume, iso-osmotic solutions has had to be made heretofore. This invention describes a low volume, hyperosmotic solution consisting of sulfate salts with and with out polyethylene glycol. Unlike prior art, this composition is useful for the cleansing of the bowel and, in lower volumes, as a laxative, without producing clinically significant changes in bodily function.
    Type: Application
    Filed: April 30, 2002
    Publication date: October 30, 2003
    Inventor: Mark vB. Cleveland
  • Patent number: 6224864
    Abstract: Antibiotic 10381a1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C1 to C3 alkyl ester of antibiotic 10381a1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: May 1, 2001
    Assignee: Pharmacia & Upjohn Company
    Inventors: Alexander D. Argoudelis, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
  • Patent number: 6214340
    Abstract: This invention provides a physiologically active substance having a strong dipeptidyl peptidase IV inhibitory activity. The physiologically active substance sulphostin is obtained by culturing a microorganism belonging to the genus Streptomyces and having an ability to produce the physiologically active substance sulphostin, producing and accumulating this substance in the cultures, and harvesting it from the cultures.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: April 10, 2001
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Tomio Takeuchi, Masa Hamada, Yasuhiko Muraoka, Tetsuo Akiyama, Masatoshi Abe, Hiroshi Naganawa, Yoshikazu Takahashi
  • Patent number: 6159443
    Abstract: A method of delivering an active agent to a target tissue, particularly neoplastic tissue, vascular anomaly or tumor tissue, in a vertebrate subject. The method includes the steps of exposing the target tissue to ionizing radiation; and administering a delivery vehicle to the vertebrate subject before, after, during, or combinations thereof, exposing the target tissue to the ionizing radiation. The delivery vehicle includes the active agent and delivers the agent to the target tissue. Exemplary delivery vehicles include platelets; leukocytes; proteins or peptides which bind activated platelets; antibodies which bind activated platelets; microspheres coated with proteins or peptides which bind activated platelets; liposomes conjugated to platelets, leukocytes, proteins or peptides which bind activated platelets, or antibodies which bind activated platelets; and combinations thereof.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: December 12, 2000
    Assignee: Vanderbilt University
    Inventor: Dennis E. Hallahan
  • Patent number: 6106836
    Abstract: The present invention relates to a vaccine container that contains one or more freeze-dried vaccine components. The vaccine component or components are present in two or more freeze-dried bodies, at least one of which is a lyosphere.Furthermore, the invention relates to methods for the preparation of such a vaccine container.Also, the invention relates to a vaccine pack, comprising the vaccine container.
    Type: Grant
    Filed: February 17, 1999
    Date of Patent: August 22, 2000
    Assignee: Akzo Nobel N.V.
    Inventors: Antonius Theodorus Maria Wilderbeek, Hans Almer Middelbeek
  • Patent number: 6093381
    Abstract: Disclosed is a method for improving the treatment of a cancer patient which is undergoing (adjuvant) chemotherapy. Prior to or concomitant with the patient receiving adjuvant chemotherapy, the patient is administered mitogenically stimulated lymph node lymphocytes or the supernatant therefrom. The lymph node lymphocytes are patient excised lymph node lymphocytes enriched in tumor reactive cells, such as CD4+ tumor reactive cells. Radiolabeled locators (e.g., antibodies) can be used along with a portable radiation detector to intraoperatively determine which lymph nodes bear lymph node lymphocytes enriched in tumor reactive cells. The patient excised lymph node lymphocytes enriched in tumor reactive cells then are subjected to mitogenic stimulation for their expansion and administration to the patient.
    Type: Grant
    Filed: December 10, 1997
    Date of Patent: July 25, 2000
    Assignee: Neoprobe Corporation
    Inventors: Pierre L. Triozzi, Julian A. Kim
  • Patent number: 5997846
    Abstract: The present invention provides a method for detecting chitin-containing organisms on an area of a person or animal by contacting the particular area with a dye that is capable of biding to chitin and emitting fluorescence upon exposure to light. If a chitin-containing organism is present in the treated area, the chitin of the organism will bind the dye and, upon exposure to light, the chitin-containing organisms may be visualized and removed. Also provided by the present invention are solutions and suspensions that contain a dye capable of binding to a chitin-containing organism and emitting florescence upon exposure to light. The solutions and suspensions provided herein may be in the form of a shampoo, cream, lotion or detergent for the detection of chitin-containing organisms present in body hair, on the skin, clothing or the fur of animals. The solutions and suspensions may also be in a form suitable for spraying on clothes, as well as on the hair, skin and fur.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: December 7, 1999
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Edward R. Burns, Murray Wittner, Fagie Faskowitz
  • Patent number: 5985281
    Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: November 16, 1999
    Assignee: Zeneca Limited
    Inventors: Christopher John Taylorson, Hendrikus Johannes Eggelte, Antonio Tarragona-Fiol, Brian Robert Rabin, Francis Thomas Boyle, John Frederick Hennam, David Charles Blakey, Peter Robert Marsham, David William Heaton, David Huw Davies, Anthony Michael Slater, Laurent Francois Andre Hennequin
  • Patent number: 5985274
    Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 16, 1999
    Assignee: Pharmacia & Upjohn Company
    Inventors: Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
  • Patent number: 5981234
    Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 9, 1999
    Assignee: Pharmacia & Upjohn Company
    Inventors: Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
  • Patent number: 5948405
    Abstract: Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity.Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: September 7, 1999
    Assignee: Crinos Industria Farmacobiologica S.p.A.
    Inventors: Armando Cedro, Roberto Porta, Franco Cattaneo, Fabio Trento, Laura Ferro, Ennio Lanzarotti
  • Patent number: 5902583
    Abstract: The present invention provides a method to achieve radioisotopic localization at tumor sites, i.e., a method of enhancing radiolabeled ligand localization to a tumor in an individual in need of such treatment, comprising the steps of: transducing the tumor with a gene encoding a membrane expressed protein unique to the tumor; and administering to said individual a radiolabeled ligand which specifically binds to the protein. The use of gene therapy technology to induce expression of high affinity membrane molecules/receptors can enhance the specificity of radioisotope localization while the use of radioactive isotopes with the ability to deliver radiation damage across several cell diameters will compensate for less than perfect transduction efficiency.
    Type: Grant
    Filed: February 11, 1997
    Date of Patent: May 11, 1999
    Assignee: UAB Research Foundation
    Inventors: Donald J. Buchsbaum, David T. Curiel, Mohammad B. Khazaell, David Raben, Murray Stackhouse
  • Patent number: 5877147
    Abstract: Muramyl peptide compounds are useful in the prophylaxis of cancers and particularly in the treatment of precancerous lesions associated with cancers of the mucosa or epithelium.
    Type: Grant
    Filed: July 29, 1996
    Date of Patent: March 2, 1999
    Assignee: Peptech (UK) Limited
    Inventor: Boris Vladimirovich Pinegin
  • Patent number: 5843890
    Abstract: The present invention is directed to new antibiotic substances denominated antibiotic GE 2270 factors B.sub.1, B.sub.2, C.sub.1, C.sub.2, D.sub.1, D.sub.2, E and T, the addition salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them and their use as animal growth promoters.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 1, 1998
    Assignee: Gruppo Lepetit S.p.A.
    Inventors: Enrico Selva, Paolo Tavecchia, Ermenegildo Restelli, Pietro Ferrari, Maurizio Denaro
  • Patent number: 5814295
    Abstract: The present invention is directed to a method for reliably determining lymph nodes enriched in tumor reactive cells, e.g., CD4+tumor-specific lymphocytes. This method includes the steps of administering to a patient an effective amount of a radiolabeled locator which specifically binds a marker produced by or associated with neoplastic tissue. Time is permitted to elapse following the administration for the radiolabeled locator to preferentially concentrate in any neoplastic tissue and for unbound radiolabeled locator to be cleared, so as to increase the ratio of photon emissions from neoplastic tissue to background photon emissions in the patient. After the time has elapsed, the patient is accessed with a radiation detection probe for determining lymph node sites exhibiting accretion of the radiolabeled locator by detecting with the probe elevated levels of radiation at the lymph node sites.
    Type: Grant
    Filed: July 13, 1994
    Date of Patent: September 29, 1998
    Assignee: The Ohio State University Research Foundation
    Inventors: Edward W. Martin, Jr., Brian J. Czerniecki, Pierre L. Triozzi, Julian A. Kim
  • Patent number: 5807840
    Abstract: The present invention discloses a method for treating patients having the CDV associated symptoms or animals carrying or infected by the canine distemper virus (CDV) or having antibodies against the CDV using Product R, a peptide-nucleic acid preparation.
    Type: Grant
    Filed: November 4, 1997
    Date of Patent: September 15, 1998
    Assignee: Advanced Viral Research Corp.
    Inventor: Shalom Z. Hirschman
  • Patent number: 5804186
    Abstract: A nerve cell differentiation promoter which comprises a physiologically active substance NK175203 or a pharmacologically acceptable salt thereof as an active ingredient is provided. It is expected that the nerve cell differentiation promoter of the present invention is applicable to a medicine for dementia, a nerve cell protective medicine or a medicine for peripheral neuropathy caused by anticancer agents.
    Type: Grant
    Filed: November 13, 1996
    Date of Patent: September 8, 1998
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Daisuke Komagata, Tomio Morino
  • Patent number: 5785949
    Abstract: A drink adapted to be consumed by a patient to enable measurement of gastric emptying of the liquid phase, is a fruit juice having mixed and suspended therein a quantity of Spirulina platensis alga grown in a .sup.13 CO.sub.2 atmosphere. These single cell organisms pass from the stomach into the small intestine where they are digested, absorbed and oxidized to produce a detectible rise in the level of .sup.13 CO.sub.2 in the patient's breath which is sampled and the measured valves plotted to enable determination of gastric emptying rate abnormalities.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: July 28, 1998
    Assignee: Meretek Diagnostics
    Inventor: Peter D. Klein
  • Patent number: 5736510
    Abstract: Antibiotics 10381v, w, x, y, z1, z2, pre-b and t are antibiotics producible by culturing the microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. The structure of Antibiotic 10381y is given below as formula IV. These antibiotics inhibit the growth of selected species of bacteria and may also be useful as a growth promotant in animals.
    Type: Grant
    Filed: March 7, 1996
    Date of Patent: April 7, 1998
    Assignee: Pharmacia & Upjohn Company
    Inventors: Charles Peter Cornell, Stephen Howard Grode, Heinz F. Meyer
  • Patent number: 5707602
    Abstract: A biscuit adapted to be ingested by a patient to enable measurement of gastric emptying has added prior to baking Spirulina Platensis alga grown in a .sup.13 CO.sub.2 atmosphere. These single cell organisms are oxidized after digestion in the small intestine to produce a detectible rise in level of .sup.13 CO.sub.2 in the patient's breath which is sampled and plotted to enable diagnosis of abnormal gastric emptying rates.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: January 13, 1998
    Assignee: Meretek Diagnostics
    Inventor: Peter D. Klein
  • Patent number: 5695984
    Abstract: Antibiotic 10381a.sub.1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C.sub.1 to C.sub.3 alkyl ester of antibiotic 10381a.sub.1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a.sub.1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 9, 1997
    Assignee: Pharmacia & Upjohn Company
    Inventors: Alexander D. Argoudelis, deceased, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
  • Patent number: 5690903
    Abstract: Methods for the preparation and use of a biological delivery system are disclosed. The method of preparation includes the loading of a non-biological material into a biostructure having a load-bearing structure. The method also includes the removal of some of the biostructure's contents and the loading of a non-biological material into the biostructure. The biostructure is biologically compatible with the host, and preferably is derived from the host, the host's species or a related species. The loaded biostructure is used directly, or it can be targeted to specific cells, tissues and/or organs within a host. The targeted biostructure can be used to deliver the non-biological material to a specified tissue, organ or cell within a host for diagnostic, therapeutic or other purposes.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: November 25, 1997
    Inventor: James F. Hainfeld
  • Patent number: 5665328
    Abstract: Compounds, compositions, their methods of preparation and use in binding bio-affecting substances to the surface membrane of bioparticles, such as enkaryotic cells, without producing appreciable detrimental effect on morphology or physiological function of cells.
    Type: Grant
    Filed: December 1, 1992
    Date of Patent: September 9, 1997
    Assignee: Phanos Technologies, Inc.
    Inventors: Paul Karl Horan, Sue Ellen Slezak, Bruce D. Jensen
  • Patent number: 5635207
    Abstract: In accordance with the present invention, there are provided compositions useful for the in vivo delivery of a biologic, wherein the biologic is associated with a polymeric shell formulated from a biocompatible material. The biologic can be associated with the polymeric shell itself, and/or the biologic, optionally suspended/dispersed in a biocompatible dispersing agent, can be encased by the polymeric shell. In another aspect, the biologic associated with polymeric shell is administered to a subject, optionally dispersed in a suitable biocompatible liquid.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 3, 1997
    Assignee: Vivorx Pharmaceuticals, Inc.
    Inventors: Mark W. Grinstaff, Patrick Soon-Shiong, Michael Wong, Paul A. Sandford, Kenneth S. Suslick, Neil P. Desai
  • Patent number: 5567676
    Abstract: The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 22, 1996
    Assignee: Gruppo Lepetit S.p.A
    Inventors: Enrico Selva, Grazia Beretta, Angelo Borghi, Maurizio Denaro
  • Patent number: 5514649
    Abstract: The present invention is directed to a new antibiotic substance denominated antibiotic GE 2270 factor C.sub.2a, the addition salts thereof, the pharmaceutical compositions thereof and its use as medicament, particularly in the treatment of infectious diseases involving microorganisms susceptible to it and its use as animal growth promoter.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: May 7, 1996
    Assignee: Gruppo Lepetit S.p.A.
    Inventors: Enrico Selva, Sergio Stella, Luigi Colombo, Maurizio Denaro
  • Patent number: 5505944
    Abstract: Physiologically active substance NK175203 is produced by culturing bacteria belonging to the genus Streptomyces and capable of producing the physiologically active substance NK175203, and collecting the produced and accumulated substance. The physiologically active substance NK175203 is useful as an effective ingredient of a pharmaceutical composition for promoting proliferation of bone marrow cells.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: April 9, 1996
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Tomio Morino, Ayako Nakatani, Masayuki Kitagawa, Masaya Sato, Takashi Harada, Seiichi Saito
  • Patent number: 5443813
    Abstract: Methods for the preparation and use of a biological delivery system are disclosed. The method of preparation includes the loading of a non-biological material into a biostructure having a load-bearing structure. The method also includes the removal of some of the biostructure's contents and the loading of a non-biological material into the biostructure. The biostructure is biologically compatible with the host, and preferably is derived from the host, the host's species or a related species. The loaded biostructure is used directly, or it can be targeted to specific cells, tissues and/or organs within a host. The targeted biostructure can be used to deliver the non-biological material to a specified tissue, organ or cell within a host for diagnostic, therapeutic or other purposes.
    Type: Grant
    Filed: June 6, 1991
    Date of Patent: August 22, 1995
    Assignee: Associated Universities, Inc.
    Inventor: James F. Hainfeld
  • Patent number: 5420136
    Abstract: A class of predominantly hydrophobic non-azo N-substituted 1,8-naphthalimide compounds, each bearing, at its 3-position, a nucleofuge and, at its 4-position, a heteroatomic electron-releasing group. The heteroatomic electron-releasing group is being characterized as having a heteroatom directly linked to the 4-position of the ring, and having at least one hydrogen directly attached to the heteroatom. Upon activation by an activating agent in an environment independent of the presence or absence of oxygen, these compounds generate activated species. The activated species initiate chemical changes in lipid bilayer membranes of viruses and other target cells. These changes can eradicate viruses and other target cells. The activated species can also cause structural changes in lipid and any associated proteins and polypeptides at a level beneath the surface of the membrane, leading to polymerization and crosslinking.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: May 30, 1995
    Assignee: MicroBioMed Corporation
    Inventors: David E. Lewis, Ronald E. Utecht, Millard M. Judy, J. Lester Matthews
  • Patent number: 5401709
    Abstract: The antibiotic AB-041 is described, obtained by controlled aerobic cultivation of Streptomyces sp. NCIMB 40428 in an aqueous culture medium. The antibiotic AB-041 exhibits biological activity, and in particular herbicidal activity.
    Type: Grant
    Filed: December 1, 1992
    Date of Patent: March 28, 1995
    Assignee: Ministero dell `Universita` e della Ricerca Scientifica e Tecnologica
    Inventors: Nunzio Andriollo, Alessandro Scacchi, Giorgio E. Borgonovi, Giorgio Cassani, Silvia Spera, Gianfranco Guglielmetti, Giorgio Pirali, Giovanni Confalonieri
  • Patent number: 5364624
    Abstract: A degenerative disease selected from the group consisting of cystic fibrosis, chronic bronchitis and bronchiectasia is treated by administering to a subject a therapeutically effective amount of WS7622A mono-or disulfate or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 7, 1993
    Date of Patent: November 15, 1994
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Shigehiro Takase, Hiroshi Hatanaka, Masami Ezaki, Eisaku Tsujii, Masanori Okamoto, Nobuharu Shigematsu, Masakuni Okuhara
  • Patent number: 5306496
    Abstract: Novel antibiotics NK374186A, NK374186B, NK374186B3 and NK374186C3 having antibacterial, antineoplastic, immunomodulation, and liver regeneration promoting activities are provided.NK374186A, NK374186B, NK374186B3 and NK374186C3 are obtained by culturing NK374186 strain (FERM P-12285) (FERM-BP 3870) belonging to the genus Penicillium. NK374186A is a compound represented by a rational formula of C.sub.34 H.sub.61 N.sub.3 O.sub.12 S.sub.9 and having a molecular weight of M+ 735 (FD-MS m/z); NK374186B is a compound represented by a rational formula of C.sub.34 H.sub.61 N.sub.3 O.sub.9 and having a molecular weight of M+ 655 (FD-MS m/z); NK374186B3 is a compound represented by a rational formula of C.sub.34 H.sub.61 N.sub.3 O.sub.9 and having a molecular weight of M+ 655 (FD-MS m/z); and NK374186C3 is a compound represented by a rational formula of C.sub.32 H.sub.59 N.sub.3 O.sub.7 and having a molecular weight of M+ 597 (FD-MS m/z).
    Type: Grant
    Filed: June 10, 1992
    Date of Patent: April 26, 1994
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Tomio Morino, Masakazu Nishimoto, Mituyuki Nishide, Akira Masuda, Masatoshi Yamada, Eiji Kawano, Takaaki Nishikiori, Seiichi Saito
  • Patent number: 5292524
    Abstract: The invention provides loaded platelets that include an absorbed loading vehicle having associated diagnostic or therapeutic agents. A method of loading platelets with diagnostic or therapeutic agents is provided. The method includes combining a loading vehicle having associated diagnostics or therapeutic agents with platelets at sufficient concentration and temperature to allow uptake of the loading vehicle by the platelets. Also provided is a method of targeting diagnostic or therapeutic agents to platelet localizing areas. The method includes the steps of: (a) combining a loading vehicle having associated diagnostic or therapeutic agents with platelets at sufficient concentration and temperature to allow uptake of the loading vehicle by the platelets; (b) isolating the platelets from excess loading vehicle; and (c) administering the isolated platelets to an animal in an effective concentration so as to promote targeting of the isolated platelets to platelet localizing areas.
    Type: Grant
    Filed: September 6, 1991
    Date of Patent: March 8, 1994
    Assignee: California Institute of Technology
    Inventors: Roxanne Male, Wilton E. Vannier
  • Patent number: 5292510
    Abstract: WS7622A mono- or di-sulfate and pharmaceutically acceptable salts thereof. WS7622A exhibits human leukocyte elastase-inhibiting activity.
    Type: Grant
    Filed: June 11, 1991
    Date of Patent: March 8, 1994
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Shigehiro Takase, Hiroshi Hatanaka, Masami Ezaki, Eisaku Tsujii, Masanori Okamoto, Nobuharu Shigematsu, Masakuni Okuhara
  • Patent number: 5279826
    Abstract: A method for therapy of disseminated intravascular coagulation, or chronic respiratory tract infectious disease characterized by administering to a patient in need thereof an effective dose suitable for therapeutic treatment of said condition of WS7622A mono- or di-sulfate ester or their pharmaceutically acceptable salt.
    Type: Grant
    Filed: June 17, 1992
    Date of Patent: January 18, 1994
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Noriaki Inamura, Yasuhiko Shinguh, Kunio Nakahara, Yoshitada Notsu, Masanori Okamoto, Shigehiro Takase, Hiroshi Hatanaka, Masami Ezaki, Eisaku Tsujii, Nobuharu Shigematsu, Masakuni Okuhara
  • Patent number: 5276147
    Abstract: The subject of the present invention is compounds which correspond to the following general formula: ##STR1## in which R.sub.1 and R.sub.3 independently of one another represent H, an alkyl, alkenyl, cycloalkyl, aryl, arylalkyl or an alkylaryl group, a heterocycle, or groups which are unsubstituted or substituted, in particular by one or more hydroxyl or alkoxy groups or halogen;n represents an integer from 1 to 5;i in each case takes values from 1 to n for the n successive ##STR2## links; R.sub.2, R.sub.4.sup.i and R.sub.5.sup.i independently of one another represent H, an alkyl, alkenyl, aryl, alkoxy, hydroxyalkyl, alkoxyalkyl, amido, acyl or carboxyalkyl group, or a salt, or an alkyl ester of the latter; or R.sub.4.sup.i and R.sub.5.sup.i together form an oxo group ##STR3## R.sub.6 and R.sub.7 represent H, or R.sub.6 and R.sub.7 together form an oxo group ##STR4## x represents a 5- or 6-membered heterocycle which contains at least one nitrogen atom, or, in the event that ##STR5## where R.sub.8 and R.sub.
    Type: Grant
    Filed: April 19, 1990
    Date of Patent: January 4, 1994
    Assignee: Medgenix Group S.A.
    Inventors: John R. Thornback, Marcel Deblaton, Gillian F. Morgan
  • Patent number: 5229362
    Abstract: Newly-discovered antibiotic A10255 factors B, C, E, F, G, H, and J are produced by submerged aerobic fermentation of Streptomyces gardneri NRRL 15537 and NRRL 18260 or an A10255-producing variant or mutant thereof. The antibiotics are active against a wide variety of pathogenic bacteria, and also enhance feed-utilization efficiency in chickens, weanling pigs, cattle and sheep. The antibiotics can also be used to detect the thiostrepton-resistance gene in Streptomyces species.
    Type: Grant
    Filed: July 17, 1991
    Date of Patent: July 20, 1993
    Assignee: Eli Lilly and Company
    Inventors: Herbert A. Kirst, Karl H. Michel
  • Patent number: 5139778
    Abstract: The present invention is directed to new antibiotic substances denominated antibiotic GE 2270 factors A.sub.1, A.sub.2, A.sub.3 and H, the additional salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them.
    Type: Grant
    Filed: July 2, 1990
    Date of Patent: August 18, 1992
    Assignee: Gruppo Lepetit SpA
    Inventors: Enrico Selva, Paolo Tavecchia
  • Patent number: 5124150
    Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.
    Type: Grant
    Filed: March 11, 1991
    Date of Patent: June 23, 1992
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5098708
    Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.
    Type: Grant
    Filed: July 6, 1990
    Date of Patent: March 24, 1992
    Assignee: Bristol-Myers Squibb Company
    Inventors: Masataka Konishi, Mitsuaki Tsunakawa, Osamu Tenmyo, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5037651
    Abstract: Dihydro derivatives of LL-E33288, BBM-1075 FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E and CL-1724 antibiotics/antitumor agents are disclosed and described, including the degradation product of LL-E33288 antibiotics/antitumor agents dihydro-LL-E33288-pseudoaglycone.
    Type: Grant
    Filed: January 30, 1987
    Date of Patent: August 6, 1991
    Assignee: American Cyanamid Company
    Inventor: May D. Lee
  • Patent number: 5013550
    Abstract: Novel compounds, called chloropolysporins B and C, and salts thereof have antibiotic properties and would appear to be members of the class of glycopeptide antibiotics containing chlorine. They may be produced by cultivating a suitable strain of microorganism of the genus Micropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). They may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, for use as a growth-promoting agent, especially for farm animals.
    Type: Grant
    Filed: February 6, 1990
    Date of Patent: May 7, 1991
    Assignee: Sankyo Company Limited
    Inventors: Tatsuo Haneishi, Takao Okazaki, Akio Torikata, Mutsuo Nakajima
  • Patent number: 4999196
    Abstract: A novel compound, DC-107, is produced by culturing a microorganism belonging to the genus Streptomyces. It is useful as a medicine because of its antibacterial and anti-tumor activity.
    Type: Grant
    Filed: March 29, 1989
    Date of Patent: March 12, 1991
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Hirofumi Nakano, Mitsunobu Hara, Isami Takahashi, Kozo Asano, Takao Iida, Makoto Morimoto
  • Patent number: 4950477
    Abstract: This invention concerns a method of preventing a pulmonary infection by a fungus in a subject susceptible to infection by the fungus comprising administering to the subject an amount per dose in an aerosol spray of a polyene or a pharmaceutically acceptable derivative thereof, effective to prevent pulmonary infection by the fungus. This invention further discloses a method of treating pulmonary aspergillosis in a subject comprising administering to the subject an amount per dose in an aerosol spray of a polyene, e.g., amphotericin B or pimaricin, or a pharmaceutically acceptable derivative thereof effective to treat aspergillosis.
    Type: Grant
    Filed: August 23, 1988
    Date of Patent: August 21, 1990
    Assignee: Memorial Hospital For Cancer and Allied Dieseas
    Inventors: Heinz J. Schmitt, Donald Armstrong, Edward M. Bernard
  • Patent number: 4921700
    Abstract: There is provided new antitumor antibiotic substances designated herein as BBM-1675C and BBM-1675D, said substances being produced by selective chemical hydrolysis of the bioactive components BBM-1675A.sub.1 (esperamicin A.sub.1) or BBM-1675A.sub.2 (esperamicin A.sub.2). The new antitumor antibiotics exhibit both antimicrobial activity and antitumor activity.
    Type: Grant
    Filed: May 28, 1987
    Date of Patent: May 1, 1990
    Assignee: Bristol-Myers Company
    Inventor: Jerzy Golik
  • Patent number: 4918054
    Abstract: Novel compounds, called chloropolysporins B and C, and salts thereof have antibiotic properties and would appear to be members of the class of glycopeptide antibiotics containing chlorine. They may be produced by cultivating a suitable strain of miroorganism of the genus Micropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). They may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, for use as a growth-promoting agent, especially for farm animals.
    Type: Grant
    Filed: July 11, 1989
    Date of Patent: April 17, 1990
    Assignee: Sankyo Company Limited
    Inventors: Tatsuo Haneishi, Takao Okazaki, Akio Torikata, Mutsuo Nakajima, Ryuzo Enokita, Toshiaki Katayama, Seigo Iwado
  • Patent number: 4900815
    Abstract: A sulfated polysaccharide DS4152 useful as an angiogenesis inhibitor or antitumor agent is provided selectively. As the sodium salt, it has the following physicochemical characteristics. Molecular weight by the gel filtration method: 29,000.+-.3,000. Elemental analysis: C: 24.42-25.76%, H: 3.34-3.98%, N: 0.51-0.89%, S: 10.6-11.7% and P: 0.77-1.06%. Sugar and protein contents: Sugar content (%): 57.+-.3 (by phenol sulfuric acid method; standard: galactose). Protein content (%): 1.+-.0.5 (by the Lowry-Folin's method; standard: bovine serum albumin). Specific rotatory power [.alpha.].sub.D.sup.25 : -37.degree..+-.1.degree. (0.5% aq. solution). Characteristic absorption bands in infrared absorption spectrum: 1240, 840 (shoulder), 810 (cm.sup.-1 ; KBr).
    Type: Grant
    Filed: May 20, 1987
    Date of Patent: February 13, 1990
    Assignee: Daiichi Seiyaku Co., Ltd.
    Inventors: Noriko Tanaka, Kazuhiro Inoue, Hiroshi Korenaga, Hidemasa Ogawa